Executive Summary of the Asian Pacific Society of Nephrology Clinical Practice Guideline on Diabetic Kidney Disease—2025 Update

作者：Adrian Liew, Sunita Bavanandan, Chuan‐Ming Hao, Soo Kun Lim, Narayan Prasad, Manisha Sahay, Paweena Susantitaphong, Veena Roberts, Eranga Wijewickrama, Muh Geot Wong, Sydney Tang · 发表于：Nephrology · 年份：2025 · DOI：10.1111/nep.70031 · 被引用次数：6 · 研究领域：Clinical practice guidelines implementation、Chronic Kidney Disease and Diabetes、Blood Pressure and Hypertension Studies

In the 2023 iteration of the United States Renal Data System (USRDS) report, the top 5 countries in the world with diabetic kidney disease (DKD) as the cause of kidney failure (KF) were all from the Asia-Pacific region. Moreover, South Korea, Singapore and Taiwan had the highest yearly change in the incidence of dialysis-treated KF from 2011 to 2021 [1]. It is, therefore, unsurprising that DKD is a significant healthcare burden for the Asia-Pacific countries, with a considerable amount of the countries' medical expenditure being spent on kidney replacement therapy (KRT) [2]. Specifically, the differences in healthcare infrastructure, resources and cultural beliefs amongst the Asia-Pacific countries have resulted in the heterogeneity of care and outcomes for people with DKD in the region. The Asian Pacific Society of Nephrology (APSN) consequently commissioned a Working Group (WG) in 2020 to develop a set of clinical guidelines on the management of DKD, and in particular, to pay attention to nuances in healthcare delivery across different countries in the region, with the aim of making these guidelines applicable and implementable. Since the publication of the APSN clinical practice guideline on DKD in 2020, new studies have emerged with data either strengthening the rationale for the use of existing treatment or supporting the addition of novel therapies in improving the outcome of people living with DKD. DKD remains a predominant cause of KF requiring KRT in the Asia-Pacific...